



**EMERGING APPROACHES TO TREATING
SPIKE PROTEIN-INDUCED DISEASES**

April 28-29, 2023 • Fort Worth, Texas


REPORT OF THREE CASES & USE OF THREE DIFFERENT DRUG COMBINATIONS

Presented By:

HECTOR CARVALLO

ROBERTO HIRSCH

BUENOS AIRES, ARGENTINA



HOW IT ALL STARTED

ClinicalTrials.gov Identifier: NCT04425863

ClinicalTrials.gov Identifier: NCT04425850

Submitted: April 2020

Finished with results: July 2020

Ivermectin IN Long-Covid Patients: A Retrospective Study

Del Franco Haroldo^{1*}, Carvallo Hector², Hirsch Roberto³

¹Neumologist, Mercante Public Hospital, Argentina

²Professor of Internal Medicine, U.A.I, Argentina

³Professor of Professor of Infectology, U.B.A. Buenos Aires, Argentina

Abstract

Long COVID convalescence has become a major issue in COVID infection. The variety and magnitude of sequelae has, so far, baffled scientific community, and no measure has proved to be both useful and reliable in diminishing and/or shortening it. We are summarising the outcomes in 856 patients previously admitted at a Public Hospital in the Province of Buenos Aires, due to moderate/severe COVID infection, who surmounted the infection and could be released later on.

We selected those whose symptoms, and mainly, the duration of them- could be attributed to long convalescence (long haulers).

In them, a simple post-COVID treatment with ivermectin (IVM) was applied, thus provoking a faster reduction of manifestations.

Keywords: long COVID, Ivermectin, long haulers.



2020

Post Covid Differences between Long-Covid and Covid Sequelae Treatment Options for Both Conditions

Carvallo Héctor E¹ and Hirsch Roberto R^{2*}

¹Former Professor of Internal Medicine, U.B.A., U.A.I. and U. Malmonides, Argentina

²Director Infectology Department, Muñiz Hospital, Argentina

*Corresponding Author: Hirsch Roberto R, Director Infectology Department, Muñiz Hospital, Argentina.

Received: May 10, 2021; Published: May 28, 2021

Abstract

SARS COV2 pandemic has become the most formidable challenge modern Medicine has ever encountered. Newly released pharmacological compounds and sera have shown deceptive outcomes, while repurposed drugs are still waiting their generalized admittance. Vaccines, though always the most preferable option, have shown decreasing efficacy in the new COVID variants. In the meantime, millions of lives are being unnecessarily lost. Confusion still prevails over certainty and that may be applied not only to illness but also (and mainly) to convalescence. Post COVID, long COVID, and COVID sequelae, are entities which happen to be mixed-up, taken for one another, and mostly misunderstood. So are the pharmacological options to manage them. In this article, we develop the clinical, pathophysiological and statistical differences between them, and also include therapeutic options that have proved their efficacy in each case, such as ivermectin + a combination of magnesium, vitamin D and HMB (hydroxymethylbutyrate) in Long COVID; and aerosol-carried corticosteroids + hypertonic-chloride-sodium solution in lung fibrotic sequelae.

Keywords: SARS COV2; COVID; HMB (Hydroxymethylbutyrate); Vitamin D



2021



CASE # 1

Male, 65 years, Argentinian, MD

No previous co-morbidities

Contracted COVID at Chiapas (MX), 2021

Treated only for symptoms

Kept suffering brain fog and severe muscle pain for over 3 months after «treatment»

Received IVM + HMB + Vit. D

Pains disappeared in a week

Brain fog in two weeks

PROTOCOLO PARA CASOS PROLONGADOS Y/O CRÓNICOS

IVERCASS (ivermectina): 0,2 mg por kilo de peso, por vía oral, una vez por semana

REVERSAL SPORT contiene  HMB 3g
Vitamina D 800 UI
Magnesio 400 mg

1 sobre diluido en agua, 1 vez por día

CASE # 2

Male, 49 years, Argentinian, Catholic Priest

Previous HIV diagnosis (2011), CD4 count within normal figures, finished treatment in 2017. Viral load undetectable.


Contracted COVID at Buenos Aires, 2022

Received IVM 1-3-5 days

Kept suffering brain fog and chronic fatigue for over 2 months.

Received IVM + Vit. D + Aspirin

Symptoms disappeared in a week



CASE # 3

Male, 61 years, Peruvian, Journalist

Diabetes Mellitus; Obesity

Had a stroke after 1st booster (2022)


Left hemiparesia

Brain fog, generalized arthralgia and diarrhea for over 4 months.

Received ZIPAD Protocol


Brain fog, arthralgia and diarrhea disappeared in three weeks.

Continues rehabilitation.




THEORIES ON LONG COVID

Immune dysregulation




Immune dysregulation, with or without reactivation of underlying pathogens, including herpesviruses such as EBV and HHV-6

Microbiota dysbiosis



Impacts of SARS-CoV-2 on the microbiota and virome (including SARS-CoV-2 persistence)

Autoimmunity and immune priming




Autoimmunity and primed immune cells from molecular mimicry

Blood clotting and endothelial abnormalities



Microvascular blood clotting with endothelial dysfunction


Dysfunctional neurological signalling



Dysfunctional signalling in the brainstem and/or vagus nerve

Properties of an Ideal Drug

- Effectiveness
- Safety
- Selectivity
- Reversible action
- Predictability
- Ease of administration
- Minimal drug interactions
- Low cost
- Chemical stability
- Possession of a simple generic name



Desiderata for Ideal Algorithms in Health Care



Explainable

conveys the relative importance of features in determining outputs



Dynamic

captures temporal changes in physiologic signals and clinical events



Precise

data frequency matches physiology, architecture is aptly complex



Autonomous

executes without time-consuming, manual data entry



Fair

evaluates and mitigates implicit bias and social inequity



Reproducible

validated externally and prospectively, shared with research communities

IS «ONE-SIZE-FITS-ALL» POSSIBLE?



NO

WHICH IS THE BEST PROTOCOL?

THE ONE THAT SUITS
YOUR PATIENT





THANK YOU

